FESS for CRSsNP Refractory to Medical Management
FESS should be offered to patients with CRSsNP who remain symptomatic despite appropriate medical therapy, as surgery significantly improves quality of life, symptom scores, and endoscopic findings compared to continued medical management alone. 1
Evidence Supporting FESS
The 2025 AAO-HNS Clinical Practice Guideline provides the framework for surgical decision-making in CRS 1. The guideline recommends offering sinus surgery when anticipated benefits exceed nonsurgical management alone, there is clarity regarding outcomes, and the patient understands expectations for long-term disease management (KAS 6) 1.
Key Guideline Principles:
- Verify the CRS diagnosis meets established criteria (symptoms plus objective findings) before considering surgery (Strong Recommendation, KAS 1A) 1
- Assess surgical candidacy based on symptoms, disease characteristics, quality of life, and prior therapy (Strong Recommendation, KAS 1B) 1
- Do not require a predefined "maximal medical therapy" regimen as prerequisite to surgery—the term "appropriate" medical therapy is preferred, as consensus on what constitutes "maximal" therapy is lacking (Recommendation, KAS 2) 1
Research Evidence Favoring FESS:
A 2017 systematic review and meta-analysis demonstrated that ESS significantly improved disease-specific quality of life scores (p < 0.00001) and nasal endoscopy scores (p < 0.00001) compared to continued medical therapy in patients refractory to appropriate medical treatment 2. This represents the highest-quality pooled evidence available.
Multiple prospective studies support these findings:
A 2014 prospective crossover study showed patients with severe baseline QOL impairment (mean SNOT-22 of 57.6) worsened with continued medical therapy (66.1, p=0.006) but improved dramatically after FESS (16.0, p<0.001), with concurrent reductions in work days lost and medication consumption 3
A 2013 Chinese multicenter trial in moderate-to-severe CRSsNP found FESS+MMT achieved faster symptom improvement and higher patient satisfaction (2x more "very satisfied" patients) compared to MMT alone, though both groups showed <5% treatment failure rates 4
A 2014 Korean study demonstrated sustained superiority of FESS over conservative therapy at 12 months, with better patient-reported outcomes (p<0.001) 5
Evidence Against FESS
The primary evidence questioning FESS efficacy comes from a 2006 Cochrane review, which concluded that available evidence did not demonstrate FESS superiority over medical treatment with or without sinus irrigation 6. However, this review has critical limitations:
- Outdated methodology: Published in 2006, predating modern surgical techniques and outcome measures
- Limited applicability: Only 3 RCTs met inclusion criteria, with small sample sizes risking type II error
- Patient selection: Did not specifically focus on medically refractory patients with severe QOL impairment
- Contradicted by subsequent evidence: The 2017 meta-analysis 2 and multiple prospective studies 4, 3, 5 demonstrate clear benefits
This older Cochrane review should not guide current practice given the substantial body of more recent, higher-quality evidence supporting FESS in appropriately selected patients.
Clinical Decision Algorithm
When to Offer FESS for CRSsNP:
- Confirmed diagnosis: Symptoms ≥12 weeks PLUS objective evidence (endoscopy or CT)
- Failed appropriate medical therapy: Nasal saline irrigation + intranasal corticosteroids for reasonable duration (not arbitrarily defined)
- Significant QOL impairment: Particularly SNOT-22 ≥30 or equivalent disease-specific measure
- Patient understanding: Realistic expectations about chronicity, potential relapse, and need for ongoing medical management post-surgery
Preoperative Requirements:
- Obtain fine-cut CT scan for surgical planning if not already available 1
- Do not base surgical extent solely on CT findings (mucosal thickening, opacification levels)—use clinical judgment 1
- Counsel patients about postoperative care: pain control, debridement, continued medical therapy, activity restrictions, return to work, follow-up schedule, and revision surgery possibility 1
Important Caveats:
CRSsNP differs from CRSwNP: The guideline specifically notes that certain CRS subtypes (polyps, bony erosion, eosinophilic mucin, fungal balls) benefit most from surgery and are least likely to benefit from continued medical therapy alone (KAS 4) 1. While this emphasizes polyp disease, the principle applies to selecting appropriate surgical candidates.
Surgery does not cure CRS: FESS facilitates medication delivery and secretion clearance but does not modify underlying inflammation 7. Patients require long-term medical management post-operatively—those unable or unwilling to continue topical therapies may not benefit 7.
Follow-up is mandatory: Routinely assess outcomes between 3-12 months post-surgery through symptom relief, quality of life measures, complications, and adherence to medical therapy 1.
Bottom Line
For patients with CRSsNP who have failed appropriate medical therapy and have significant QOL impairment, FESS provides superior outcomes compared to continued medical management alone. The 2025 AAO-HNS guidelines support this approach with formal recommendations 1, and the highest-quality meta-analytic evidence demonstrates significant improvements in both objective and subjective measures 2. The decision should be individualized based on symptom severity, QOL impact, and patient willingness to engage in long-term postoperative medical management, but surgery should be offered when benefits clearly exceed continued medical therapy alone.